Printer Friendly

Teva Announces Tentative Approval for Generic Cozaar(R) Tablets.

JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Merck's antihypertensive agent Cozaar(R) (Losartan Potassium) Tablets, 25 mg, 50 mg and 100 mg. Final approval of this ANDA is expected in April 2010 when patent protection for the brand product expires.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80% of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic products, the impact of competition from brand-name companies that sell or license their own brand products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic product, the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding litigation, including that relating to the generic versions of Allegra(R), Neurontin(R), Oxycontin(R) and Zithromax(R), the effects of competition on Copaxone(R) sales, including as a result of the expected reintroduction of Tysabri(R) into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities, environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:Teva Announces Tentative Approval for Generic Cozaar(R) Tablets.
Publication:Business Wire
Geographic Code:7ISRA
Date:May 28, 2006
Words:508
Previous Article:Goldleaf Technologies Responds to Phishing Attempt.
Next Article:Rock Creek Outfitters Leases Space at Two North Shore.
Topics:


Related Articles
Teva Announces Tentative Approval of Gatifloxacin Tablets.
Teva Announces Approval of Azithromycin Tablets.
Teva Announces Tentative Approval of Zaleplon Capsules.
Teva Announces Tentative Approval of Divalproex Sodium Delayed-Release Tablets.
Teva Announces Approval of Desmopressin Acetate Tablets.
Teva Announces Tentative Approval of Topiramate Tablets, 50 mg.
Teva Announces Tentative Approval of Simvastatin Tablets; Provides Update on 180-Day Exclusivity.
Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets.
FDA APPROVES TEVA'S ANDA TO MARKET GENERIC VERSION OF ZOCOR.
Teva Provides Update on Generic Aciphex(R) Litigation.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters